• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

胰腺癌亚型的蛋白质基因组分析。

Proteogenomic analysis of pancreatic cancer subtypes.

机构信息

Department of Biomedical Sciences, School of Health Sciences, University of Zambia, Lusaka, Zambia.

Department of Pathology and Microbiology, School of Medicine, University of Zambia, Lusaka, Zambia.

出版信息

PLoS One. 2021 Sep 10;16(9):e0257084. doi: 10.1371/journal.pone.0257084. eCollection 2021.

DOI:10.1371/journal.pone.0257084
PMID:34506537
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8432812/
Abstract

Pancreatic cancer remains a significant public health problem with an ever-rising incidence of disease. Cancers of the pancreas are characterised by various molecular aberrations, including changes in the proteomics and genomics landscape of the tumour cells. Therefore, there is a need to identify the proteomic landscape of pancreatic cancer and the specific genomic and molecular alterations associated with disease subtypes. Here, we carry out an integrative bioinformatics analysis of The Cancer Genome Atlas dataset, including proteomics and whole-exome sequencing data collected from pancreatic cancer patients. We apply unsupervised clustering on the proteomics dataset to reveal the two distinct subtypes of pancreatic cancer. Using functional and pathway analysis based on the proteomics data, we demonstrate the different molecular processes and signalling aberrations of the pancreatic cancer subtypes. In addition, we explore the clinical characteristics of these subtypes to show differences in disease outcome. Using datasets of mutations and copy number alterations, we show that various signalling pathways previously associated with pancreatic cancer are altered among both subtypes of pancreatic tumours, including the Wnt pathway, Notch pathway and PI3K-mTOR pathways. Altogether, we reveal the proteogenomic landscape of pancreatic cancer subtypes and the altered molecular processes that can be leveraged to devise more effective treatments.

摘要

胰腺癌仍然是一个严重的公共卫生问题,其发病率不断上升。胰腺肿瘤的特征是各种分子异常,包括肿瘤细胞的蛋白质组学和基因组学景观的改变。因此,有必要确定胰腺癌的蛋白质组学景观以及与疾病亚型相关的特定基因组和分子改变。在这里,我们对包括来自胰腺癌患者的蛋白质组学和全外显子测序数据在内的癌症基因组图谱数据集进行综合生物信息学分析。我们对蛋白质组学数据集进行无监督聚类,以揭示两种不同的胰腺癌亚型。使用基于蛋白质组学数据的功能和途径分析,我们证明了胰腺癌亚型的不同分子过程和信号异常。此外,我们还探讨了这些亚型的临床特征,以显示疾病结果的差异。使用突变和拷贝数改变数据集,我们表明先前与胰腺癌相关的各种信号通路在两种胰腺癌亚型中均发生改变,包括 Wnt 通路、Notch 通路和 PI3K-mTOR 通路。总之,我们揭示了胰腺癌亚型的蛋白质基因组景观以及可以利用的改变分子过程,以设计更有效的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e156/8432812/ff31346c0a60/pone.0257084.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e156/8432812/4bad14a1dfca/pone.0257084.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e156/8432812/a2e3db588f7a/pone.0257084.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e156/8432812/043189453e9e/pone.0257084.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e156/8432812/0c9754315f43/pone.0257084.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e156/8432812/ff31346c0a60/pone.0257084.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e156/8432812/4bad14a1dfca/pone.0257084.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e156/8432812/a2e3db588f7a/pone.0257084.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e156/8432812/043189453e9e/pone.0257084.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e156/8432812/0c9754315f43/pone.0257084.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e156/8432812/ff31346c0a60/pone.0257084.g005.jpg

相似文献

1
Proteogenomic analysis of pancreatic cancer subtypes.胰腺癌亚型的蛋白质基因组分析。
PLoS One. 2021 Sep 10;16(9):e0257084. doi: 10.1371/journal.pone.0257084. eCollection 2021.
2
Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma.基于蛋白质基因组学的胰腺导管腺癌的生物学特性和治疗策略研究进展
J Hematol Oncol. 2022 Nov 25;15(1):168. doi: 10.1186/s13045-022-01384-3.
3
Machine Learning and Network Analyses Reveal Disease Subtypes of Pancreatic Cancer and their Molecular Characteristics.机器学习和网络分析揭示了胰腺癌的疾病亚型及其分子特征。
Sci Rep. 2020 Jan 27;10(1):1212. doi: 10.1038/s41598-020-58290-2.
4
Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways.2002 例人类癌症的蛋白质基因组学特征分析揭示了泛癌分子亚型及相关途径。
Nat Commun. 2022 May 13;13(1):2669. doi: 10.1038/s41467-022-30342-3.
5
Genomic analysis of pancreatic cancer reveals 3 molecular subtypes with different clinical outcomes.胰腺癌的基因组分析揭示了 3 种具有不同临床结局的分子亚型。
Medicine (Baltimore). 2021 Apr 9;100(14):e24969. doi: 10.1097/MD.0000000000024969.
6
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.PI3K/AKT/mTOR信号通路改变的泛癌蛋白质基因组图谱
Cancer Cell. 2017 Jun 12;31(6):820-832.e3. doi: 10.1016/j.ccell.2017.04.013. Epub 2017 May 18.
7
Proteomic and genomic profiling of pancreatic cancer.胰腺癌的蛋白质组学和基因组学分析。
Cell Biol Toxicol. 2019 Aug;35(4):333-343. doi: 10.1007/s10565-019-09465-9. Epub 2019 Feb 15.
8
Integrated In Silico Analysis of Proteogenomic and Drug Targets for Pancreatic Cancer Survival.基于蛋白质基因组学和药物靶点的综合计算分析与胰腺癌患者生存预后的关系
Methods Mol Biol. 2023;2660:273-282. doi: 10.1007/978-1-0716-3163-8_19.
9
Current status of clinical proteogenomics in lung cancer.肺癌临床蛋白质基因组学的现状。
Expert Rev Proteomics. 2019 Sep;16(9):761-772. doi: 10.1080/14789450.2019.1654861. Epub 2019 Aug 21.
10
Integrative proteogenomic characterization of hepatocellular carcinoma across etiologies and stages.整合蛋白质基因组学分析肝癌的病因和分期特征。
Nat Commun. 2022 May 4;13(1):2436. doi: 10.1038/s41467-022-29960-8.

引用本文的文献

1
Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches.通过组学和多组学方法揭示肝内胆管癌的异质性
Cancers (Basel). 2024 Aug 20;16(16):2889. doi: 10.3390/cancers16162889.
2
Proteomics-Driven Biomarkers in Pancreatic Cancer.蛋白质组学驱动的胰腺癌生物标志物
Proteomes. 2023 Aug 7;11(3):24. doi: 10.3390/proteomes11030024.
3
Mutational landscape of cancer-driver genes across human cancers.人类癌症中癌症驱动基因的突变景观。

本文引用的文献

1
Cancer Stem Cell Marker CD44 Plays Multiple Key Roles in Human Cancers: Immune Suppression/Evasion, Drug Resistance, Epithelial-Mesenchymal Transition, and Metastasis.癌症干细胞标志物CD44在人类癌症中发挥多种关键作用:免疫抑制/逃避、耐药性、上皮-间质转化和转移。
OMICS. 2021 May;25(5):313-332. doi: 10.1089/omi.2021.0025.
2
High ELF4 expression in human cancers is associated with worse disease outcomes and increased resistance to anticancer drugs.在人类癌症中,ELF4 表达水平高与较差的疾病结局和对抗癌药物的耐药性增加有关。
PLoS One. 2021 Apr 9;16(4):e0248984. doi: 10.1371/journal.pone.0248984. eCollection 2021.
3
Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies.
Sci Rep. 2023 Aug 7;13(1):12742. doi: 10.1038/s41598-023-39608-2.
4
Proteogenomic landscape of human pancreatic ductal adenocarcinoma in an Asian population reveals tumor cell-enriched and immune-rich subtypes.亚洲人群中人类胰腺导管腺癌的蛋白质基因组图谱揭示了肿瘤细胞富集型和免疫富集型亚型。
Nat Cancer. 2023 Feb;4(2):290-307. doi: 10.1038/s43018-022-00479-7. Epub 2022 Dec 22.
5
High ELF4 expression in human cancers is associated with worse disease outcomes and increased resistance to anticancer drugs.在人类癌症中,ELF4 表达水平高与较差的疾病结局和对抗癌药物的耐药性增加有关。
PLoS One. 2021 Apr 9;16(4):e0248984. doi: 10.1371/journal.pone.0248984. eCollection 2021.
6
Integrated molecular characterisation of the MAPK pathways in human cancers reveals pharmacologically vulnerable mutations and gene dependencies.人类癌症中MAPK信号通路的综合分子特征揭示了药物敏感性突变和基因依赖性。
Commun Biol. 2021 Jan 4;4(1):9. doi: 10.1038/s42003-020-01552-6.
人类癌症中MAPK信号通路的综合分子特征揭示了药物敏感性突变和基因依赖性。
Commun Biol. 2021 Jan 4;4(1):9. doi: 10.1038/s42003-020-01552-6.
4
Machine Learning and Network Analyses Reveal Disease Subtypes of Pancreatic Cancer and their Molecular Characteristics.机器学习和网络分析揭示了胰腺癌的疾病亚型及其分子特征。
Sci Rep. 2020 Jan 27;10(1):1212. doi: 10.1038/s41598-020-58290-2.
5
Metabolic gene alterations impact the clinical aggressiveness and drug responses of 32 human cancers.代谢基因改变影响 32 种人类癌症的临床侵袭性和药物反应。
Commun Biol. 2019 Nov 14;2:414. doi: 10.1038/s42003-019-0666-1. eCollection 2019.
6
Proteome alterations in pancreatic ductal adenocarcinoma.胰腺导管腺癌中的蛋白质组改变。
Cancer Lett. 2020 Jan 28;469:429-436. doi: 10.1016/j.canlet.2019.11.020. Epub 2019 Nov 14.
7
Pan-cancer analysis of iron metabolic landscape across the Cancer Genome Atlas.癌症基因组图谱中泛癌症的铁代谢全景分析。
J Cell Physiol. 2020 Feb;235(2):1013-1024. doi: 10.1002/jcp.29017. Epub 2019 Jun 25.
8
The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability.癌症基因组图谱表达亚型分析在晚期尿路上皮癌中对检查点抑制的反应,并确定一组具有高生存概率的患者亚群。
Eur Urol. 2019 Jun;75(6):961-964. doi: 10.1016/j.eururo.2019.02.017. Epub 2019 Mar 7.
9
Proteomic and genomic profiling of pancreatic cancer.胰腺癌的蛋白质组学和基因组学分析。
Cell Biol Toxicol. 2019 Aug;35(4):333-343. doi: 10.1007/s10565-019-09465-9. Epub 2019 Feb 15.
10
Systems Biology Approach to Identify Novel Genomic Determinants for Pancreatic Cancer Pathogenesis.系统生物学方法鉴定胰腺癌发病机制的新型基因组决定因素。
Sci Rep. 2019 Jan 15;9(1):123. doi: 10.1038/s41598-018-36328-w.